| First Author | Kang L | Year | 2020 |
| Journal | Front Immunol | Volume | 11 |
| Pages | 609400 | PubMed ID | 33613532 |
| Mgi Jnum | J:313171 | Mgi Id | MGI:6791470 |
| Doi | 10.3389/fimmu.2020.609400 | Citation | Kang L, et al. (2020) CCR8 Signaling via CCL1 Regulates Responses of Intestinal IFN-gamma Producing Innate Lymphoid CelIs and Protects From Experimental Colitis. Front Immunol 11:609400 |
| abstractText | A diverse spectrum of immune cells populates the intestinal mucosa reflecting the continuous stimulation by luminal antigens. In lesions of patients with inflammatory bowel disease, an aberrant inflammatory process is characterized by a very prominent infiltrate of activated immune cells producing cytokines and chemokines. These mediators perpetuate intestinal inflammation or may contribute to mucosal protection depending on the cellular context. In order to further characterize this complex immune cell network in intestinal inflammation, we investigated the contribution of the chemokine receptor CCR8 to development of colitis using a mouse model of experimental inflammation. We found that CCR8(-/-) mice compared to wildtype controls developed strong weight loss accompanied by increased histological and endoscopic signs of mucosal damage. Further experiments revealed that this gut protective function of CCR8 seems to be selectively mediated by the chemotactic ligand CCL1, which was particularly produced by intestinal macrophages during colitis. Moreover, we newly identified CCR8 expression on a subgroup of intestinal innate lymphoid cells producing IFN-gamma and linked a functional CCL1/CCR8 axis with their abundance in the gut. Our data therefore suggest that this pathway supports tissue-specific ILC functions important for intestinal homeostasis. Modulation of this regulatory circuit may represent a new strategy to treat inflammatory bowel disease in humans. |
